Valneva SE (VALN) , a specialty vaccine company, has achieved a significant milestone with the approval of its single-dose chikungunya vaccine, IXCHIQ, by Health Canada. This approval follows the FDA's nod in November 2023 as well as the European Medicines Agency's recent recommendation for marketing authorization in Europe.This latest endorsement positions Valneva to significantly impact the chikungunya vaccine market globally.A Few Words on ChikungunyaAlso known as CHIKV, Chikungunya is a mosquito-borne v ...